Myocardial stimulation

• US 7,349,740 B2
• Filed: 07/22/2004
• Issued: 03/25/2008
• Est. Priority Date: 07/28/2003
• Status: Expired due to Fees

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: Maura, Donovan G., Soykan, Orhan
• Primary Examiner(s): Layno; Carl
• Assistant Examiner(s): Lee; Yun Haeng
• Application Number:
  US10/896,760
• Publication Number:
  US 20050043766A1
• Time in Patent Office: 1,342 Days
• Field of Search: 607/9, 607 2- 3, 607/50, 604/20
• US Class Current: 607/50
• CPC Class Codes: A61L 27/3804 characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
• CPC Class Codes: A61L 27/3839 characterised by the site of application in the body materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60
• CPC Class Codes: A61N 1/3627 for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
• CPC Class Codes: A61N 1/365 controlled by a physiological parameter, e.g. heart potential evoked response A61N1/371
• CPC Class Codes: A61N 1/368 comprising more than one electrode co-operating with different heart regions A61N1/3622, A61N1/3627 take precedence

Abstract

In general, the invention is directed to methods for electrically stimulating transplanted biological material, such as transplanted cells, to improve the performance of the heart during systole. In particular, the invention is directed to devices and techniques for stimulating biological material transplanted in a myocardium of a heart during an ejection phase of a cardiac cycle. The transplanted biological material may include cells, such as skeletal myoblasts, precursor cells, endothelial cells, differentiated or undifferentiated stem cells, undifferentiated contractile cells, fibroblasts and genetically engineered cells. In general, stimulation of the transplanted biological material during the ejection phase of the cardiac cycle, when the aortic and pulmonary valves are open, provides hemodynamic assistance to the heart.

Claims

1. A method comprising electrically stimulating biological material transplanted in a myocardium of a heart during an ejection phase of a cardiac cycle wherein said method further comprises sensing a pressure in a ventricle of a heart and wherein electrically stimulating the biological material transplanted in the myocardium comprises delivering a set stimulating pulses to the biological material in response to the pressure.

2. The method of claim 1, wherein the biological material comprises cells.

3. The method of claim 2, wherein the biological material comprises cells selected from skeletal myoblasts, differentiated stem cells, undifferentiated stem cells, fibroblasts, endothelial cells and genetically engineered cells.

4. The method of claim 1, wherein the biological material comprises genes.

5. The method of claim 1, wherein the biological material comprises a chemoattractant.

6. The method of claim 1, wherein electrically stimulating the biological material transplanted in the myocardium comprises electrically stimulating the biological material transplanted in an infarct region of the myocardium.

7. The method of claim 1, wherein electrically stimulating the biological material transplanted in the myocardium comprises electrically stimulating the biological material transplanted proximate to an infarct region of the myocardium.

8. The method of claim 1, further comprising:

sensing a biological signal; and

electrically stimulating the biological material in response to the biological signal.

9. The method of claim 8, wherein the biological signal comprises at least one of a blood pressure signal, a cardiac depolarization signal, cardiac repolarization signal, a cardiac impedance signal and a heart sound signal.

10. The method of claim 8, wherein the biological signal indicates whether the heart is in the ejection phase.

11. The method of claim 1, further comprising:

identifying an occurrence at which a maximum change of sensed pressure in the ventricle occurs during the cardiac cycle; and

electrically stimulating the biological material during the cardiac cycle after the identified occurrence.

12. The method of claim 1, further comprising:

identifying, during a first cardiac cycle, a time interval between an occurrence of a cardiac event and a maximum change of sensed pressure in the ventricle during the first cardiac cycle;

sensing the cardiac event in a second cardiac cycle; and

electrically stimulating the biological material during the second cardiac cycle after the cardiac event and the time interval.

13. The method of claim 12, wherein the cardiac event is an R-wave.

14. The method of claim 12, further comprising adjusting the time interval as a function of an occurrence of the cardiac event and a maximum change of sensed pressure in the ventricle during in a third cardiac cycle.

15. The method of claim 1, wherein electrically stimulating the biological material comprises delivering a set of stimulating pulses to the biological material.

16. The method of claim 15, wherein the set of stimulating pulses comprises approximately five pulses.

17. The method of claim 15, wherein the set of stimulating pulses comprises bipolar square wave pulses.

18. The method of claim 15, wherein the stimulating pulses are delivered to the biological material by at least two electrodes separated by a separation distance, and wherein the set of stimulating pulses comprises pulses having a voltage amplitude of approximately one volt per millimeter of separation distance.

19. The method of claim 15, wherein the set of set of stimulating pulses comprises pulses separated by approximately one one hundredth of a second.

20. The method of claim 1, wherein electrically stimulating the biological material comprises electrically stimulating the biological material with energy sufficient to cause the biological material to contract, the method further comprising electrically stimulating the biological material with energy insufficient to cause the biological material to contract.

21. The method of claim 1, further comprising:

identifying, during a first cardiac cycle, a time interval between an occurrence of a cardiac event and the ejection phase;

sensing the cardiac event in a second cardiac cycle; and

electrically stimulating the biological material during the second cardiac cycle after the cardiac event and the time interval.

22. The method of claim 21, wherein the cardiac event is an R-wave.

23. The method of claim 21, further comprising adjusting the time interval as a function of an occurrence of the cardiac event and the ejection phase in a third cardiac cycle.

24. A method comprising:

electrically stimulating biological material transplanted in a myocardium of a heart during an ejection phase of a first cardiac cycle;

suspending electrical stimulation of the biological material during the ejection phase of a second cardiac cycle;

monitoring a hemodynamic parameter during the second cardiac cycle; and

determining whether to electrically stimulate the biological material during the ejection phase of a third cardiac cycle as a function of the monitoring.

25. The method of claim 24, wherein the hemodynamic parameter comprises at least one of cardiac output, stoke volume, ventricular pressure and blood flow rate.

26. The method of claim 24, wherein determining whether to electrically stimulate the biological material during the ejection phase of the third cardiac cycle as a function of the monitoring comprises discontinuing electrical stimulation when the monitoring indicates that the biological material is ineffective in contributing to hemodynamic operation of the heart.

27. The method of claim 24, wherein determining whether to electrically stimulate the biological material during the ejection phase of the third cardiac cycle as a function of the monitoring comprises delivering electrical stimulation at a reduced per-cardiac-cycle frequency.

28. A computer-readable medium comprising instructions for causing a programmable processor to:

control delivery of electrical stimulation of biological material transplanted in a myocardium of a heart during an ejection phase of a first cardiac cycle;

suspend delivery of electrical stimulation of the biological material during the ejection phase of a second cardiac cycle;

monitor a hemodynamic parameter during the second cardiac cycle; and

determine whether to electrically stimulate the biological material during the ejection phase of a third cardiac cycle as a function of the monitoring, wherein the instructions that cause the processor to determine whether to electrically stimulate the biological material during the ejection phase of the third cardiac cycle as a function of the monitoring comprise instructions causing the processor to discontinue electrical stimulation when the monitoring indicates that the biological material is ineffective in contributing to hemodynamic operation of the heart.

29. The medium of claim 28, wherein the hemodynamic parameter comprises at least one of cardiac output, stroke volume, ventricular pressure and blood flow rate.

30. The medium of claim 28, wherein the instructions that cause the processor to determine whether to electrically stimulate the biological material during the ejection phase of the third cardiac cycle as a function of the monitoring comprise instructions causing the processor to control delivery of electrical stimulation at a reduced per-cardiac-cycle frequency.

31. A computer-readable medium comprising instructions for causing a programmable processor to:

control delivery of electrical stimulation of biological material transplanted in a myocardium of a heart during an ejection phase of a first cardiac cycle;

suspend delivery of electrical stimutation of the biological material during the ejection phase of a second cardiac cycle;

monitor a hemodynamic parameter during the second cardiac cycle; and

determine whether to electrically stimulate the biological material during the ejection phase of a third cardiac cycle as a function of the monitoring, wherein the instructions that cause the processor to determine whether to electrically stimulate the biological material during the ejection phase of the third cardiac cycle as a function of the monitoring comprise instructions causing the processor to control delivery of electrical stimulation at a reduced per-cardiac-cycle frequency.

32. The medium of claim 31, wherein the hemodynamic parameter comprises at least one of cardiac output, stroke volume, ventricular pressure and blood flow rate.

33. The medium of claim 31, wherein the instructions that cause the processor to determine whether to electrically stimulate the biological material during the ejection phase of the third cardiac cycle as a function of the monitoring comprise instructions causing the processor to discontinue electrical stimulation when the monitoring indicates that the biological material is ineffective in contributing to hemodynamic operation of the heart.